Prostate Cancer Clinical Trial
Official title:
Evaluation of Intraprostatic Fiducial Markers For Targeting of External Beam Radiation Therapy
The goal of this clinical research study is to evaluate a system for localizing (targeting for treatment) the prostate for external beam radiation therapy. The system will be used to locate the prostate before treatment and to measure movement of the prostate during treatment. The data collected with the system will be compared to CT images taken during the course of your radiation therapy treatment. Researchers will try to use this information to verify the performance of the system, which could lead to improved positioning and tracking of the prostate during treatment.
The prostate may change position on a day-to-day basis due to differences in positioning,
muscle tone, rectal filling, and bladder filling. Soft tissue like the prostate is not
usually visible with normal x-rays, but certain metals like gold are visible. Many
institutions are using an FDA-approved system (fiducial system), the one being used in this
study, which involves implanting small gold markers to locate the prostate on a daily basis.
This system allows the prostate to be located before treatment, which may improve radiation
delivery to the prostate and decrease radiation exposure to normal tissue such as the rectum
and bladder. The ability of this system to provide information on the location of the
prostate before treatment should allow for more precise and accurate radiation treatment of
prostate cancer.
The small implanted gold markers are 3 mm long and 1 mm wide (about the size of a grain of
rice). If you agree to take part in this study, 3 markers will be permanently implanted into
your prostate using a needle similar to the biopsy needle used to diagnose your cancer.
Treatment for prostate cancer during this research study will not be different from the MD
Anderson standard of care. You will have intensity-modulated radiation therapy (IMRT)
treatment for the prostate cancer performed using the CT-Linac treatment machine (ExaCT,
Varian Medical Systems, Palo Alto, CA). This machine will have the same IMRT capabilities as
other treatment machines in the Radiation Oncology Department.
During the study, the position of the gold markers seen on x-ray will be used to make
adjustments to the position of your prostate for your radiation therapy treatment. The
positions reported by the fiducial system will be recorded and used for daily treatment.
Three (3) times per week, you will have a CT scan of your prostate. The CT scans will be
performed just before the delivery of radiation. Radiotherapists will assist you onto the
treatment table and position it for your treatment. The treatment table will then be rotated
180 degrees from the treatment machine and the CT scan of your prostate will be performed.
After the CT scan, which will take about 5-8 minutes, the couch will be rotated back to the
original position.
A trans-abdominal ultrasound of your prostate will also be performed twice per week for the
first two weeks and then once a week from then on while you are on study. The MD Anderson
staff and researchers will analyze the changes in prostate movement during radiation therapy
using the scanned CT images and ultrasound images and compare them with positional changes
displayed by the fiducial-based system.
Targeting of your prostate on a daily basis will be performed using the fiducial-based
system. This will involve performing a pair of x-rays before your treatment. A shift will be
made if needed using the implanted prostate markers. The position of the seeds after the
shift will be routinely verified with another pair of x-rays. After alignment has occurred, a
radiation treatment will then be delivered.
This is an investigational study. The fiducial-based system is FDA-approved. A total of 20
patients will take part in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04081636 -
Prostate Biopsy: Efficacy and Complications
|
N/A | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Recruiting |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Active, not recruiting |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A | |
Recruiting |
NCT03668652 -
Focal Prostate Ablation Versus Radical Prostatectomy
|
N/A | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A | |
Recruiting |
NCT03700099 -
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
|
Phase 2 | |
Recruiting |
NCT04249154 -
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04219059 -
MR Radiomic Features in Prostate Cancer
|
||
Recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT00953576 -
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Recruiting |
NCT03568188 -
Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer
|
Phase 2 |